Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Core Viewpoint - Acrivon Therapeutics is advancing its clinical programs and utilizing its proprietary Generative Phosphoproteomics AP3 platform for drug discovery and development, with a focus on precision medicines [3][4]. Company Overview - Acrivon Therapeutics is a clinical stage biopharmaceutical company that develops precision medicines using its Generative Phosphoproteomics AP3 platform, which provides unbiased interpretation and quantification of drug-regulated pathway activity levels [3]. - The AP3 platform generates terabytes of proprietary data and includes tools such as the AP3 Data Portal, Kinase Substrate Relationship Predictor, and Interactome, enabling rapid and differentiated compound design [3]. Clinical Programs - The lead program, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for endometrial cancer, with Fast Track designation from the FDA [4]. - Acrivon is also developing ACR-2316, a selective WEE1/PKMYT1 inhibitor, which has shown favorable tolerability and initial clinical activity in various solid tumor types, including endometrial cancer [5]. - Additionally, Acrivon is advancing ACR-6840, a candidate targeting CDK11, as part of its internally discovered pipeline [5]. Upcoming Events - The company's president and CEO, Peter Blume-Jensen, will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 [1].